CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) has launched AlloHome™, a comprehensive patient monitoring solution aimed at enhancing care for transplant patients. This innovative technology allows patients to track vital health data at home, enabling healthcare providers to identify potential adverse events early. Studies indicate significant hospital readmission rates post-transplant, highlighting the need for continuous monitoring. CEO Reg Seeto emphasizes the importance of this tool, especially for patients in underserved communities, as it improves patient engagement and reduces complications.

Positive

• Launch of AlloHome™, a remote monitoring solution for transplant patients.
• Real-time data transmission to healthcare professionals improves early intervention.
• Potential to reduce hospital readmission rates, estimated at up to 45% for lung transplants.

Negative

• Dependence on technology may pose challenges in patient compliance.
• Forward-looking statements indicate risks related to realizing expected benefits.

AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of AlloHome™, a pan-organ patient monitoring solution that extends care into a patient’s home by capturing a range of vital health data that can help doctors with the early identification of adverse clinical events and the ability to make preemptive measures to avoid complications pre- and post-transplantation.

“CareDx is committed to driving forward innovative digital health solutions to support patients at all stages of their transplant journey and we are especially proud to deliver this new, convenient patient monitoring offering to augment their care,” said Reg Seeto, CareDx CEO and President. “AlloHome offers personalized, real-time monitoring to ensure that all patients, including those in underserved communities who may have difficulty accessing healthcare, receive the high-quality continuous oversight and care that their condition requires.”

Through AlloHome’s seamless connection to biometric devices, patients can capture their own vital sign readings at home. Through a fully integrated system, biometric results collected with the AlloHome devices will seamlessly flow into the AlloCare app without manual entry. Readings of real-time data are transmitted to trained CareDx transplant professionals who can escalate potential concerns to the patient’s doctor in a timely manner. Regular monitoring of critical patient health data through AlloHome improves continuity of care, enables the opportunity for earlier interventions, helps prevent readmission, and improves patient engagement at every step along the transplant journey.

“A big concern for me is that I often don’t know what is happening with my transplant patients until they return to the clinic or are in the emergency room presenting with an issue. Receiving a notification when my patient is showing signs of a potential problem with AlloHome remote monitoring will be extremely beneficial in driving earlier interventions,” said Matthew Mulloy, MD, Surgical Director of Abdominal Transplant Surgery, Medical City Dallas Hospital. “Additionally, access to real-time data of patient vitals helps me see a more complete picture, like watching a movie in high-definition video, in order to make more informed and timely decisions regarding my patient’s care to improve outcomes and reduce the incidence of serious complications and hospital readmission.”

Hospital readmission for patients after receiving an organ transplant is a concern for clinicians. Studies estimate that thirty two percent of patients who receive a kidney transplant,¹ nineteen percent who receive a heart transplant² and thirty to forty-five percent who receive a lung transplant³ required readmission to the hospital within thirty days after transplantation. The ninety-day hospital readmission rates for patients after transplant surgery are as high as thirty percent for certain organ types.^4,5 Long-term graft loss at five years is estimated to be twenty percent or higher across organ transplant types.^6-9 Hospital readmissions reflect a significant downturn in a patient’s health and earlier interventions enabled through personalized patient monitoring have the potential to reduce the incidence.

To learn more about CareDx AlloHome go here.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s AlloHome solution. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of CareDx’s AlloHome product; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the first quarter of 2022 ended on March 31, 2022 filed by CareDx with the SEC on May 5, 2022 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

References:

1. Hogan J, Arenson MD, Adhikary SM, et al. Assessing Predictors of Early and Late Hospital Readmission After Kidney Transplantation. Transplant Direct. 2019 Jul 29;5(8):e479. doi: 10.1097/TXD.0000000000000918.
2. Darmoch F, Al-khadra Y, Pacha HM, et al. 30-Day Readmission Causes and Rates After Heart Transplant: A Nationwide Cohort Study. Circulation. 2019; 140: A15814.
3. Simanovski J, Ralph J. Readmissions After Lung Transplantation. Progress in Transplantation. 2020; 30(4):365-367.
4. Famure O, Kim ED, Au M, et al. What Are the Burden, Causes, and Costs of Early Hospital Readmissions After Kidney Transplantation? Prog Transplant. 2021 Jun;31(2):160-167.
5. Shankar, N., Marotta, P., Wall, W., et al., Defining Readmission Risk Factors for Liver Transplant Recipients. Gastroenterology & Hepatology, 2011. 7(9):585-590.
6. Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med 2021; 385:729-743.
7. Wilhelm MJ. Long-term outcome following heart transplantation: current perspective. J Thorac Dis. 2015 Mar;7(3):549-51.
8. Mrad A, Chakraborty RK. Lung Transplant Rejection. [Updated 2022 Apr 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564391/
9. Scientific Registry of Transplant Recipients. https://srtr.transplant.hrsa.gov/annual_reports/2019/Liver.aspx. Accessed online August 1, 2022.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005596/en/

CareDx, Inc.

Anna Czene

Media Relations

818-731-2203

aczene@caredx.com



Ian Cooney

Investor Relations

415-722-4563

investor@CareDx.com

Source: CareDx, Inc.

FAQ

What is AlloHome from CareDx, Inc. (CDNA)?

AlloHome is a new patient monitoring solution designed for transplant patients to capture and transmit vital health data to healthcare providers for early intervention.

How does AlloHome improve patient care for transplant patients?

AlloHome enhances patient care by enabling real-time monitoring of health metrics, allowing for timely interventions and reducing the risk of hospital readmissions.

What are the hospital readmission rates for transplant patients that AlloHome aims to address?

Hospital readmission rates can be as high as 30% for certain organ types within 90 days post-transplant.

What potential benefits does CareDx (CDNA) foresee with AlloHome?

CareDx anticipates that AlloHome will improve patient engagement, continuity of care, and decrease serious complications through proactive health management.

How does AlloHome connect with healthcare providers?

AlloHome interfaces with biometric devices to automatically send health data to the AlloCare app, which is monitored by CareDx transplant professionals.